Expert consensus decision pathway on nonstatin therapies for LDL-c lowering
The Journal of the American College of Cardiology has published the 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk.
News - Oct. 10, 2022The Journal of the American College of Cardiology has published the 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk.
Since the 2018 AHA/ACC/multisociety cholesterol guideline, three novel nonstatin LDL-c-lowering medications have been approved by the FDA: bempedoic acid (a cholesterol biosynthesis inhibitor), evinacumab (an ANGPTL3 inhibitor), and inclisiran (a PCSK9 siRNA). The current expert consensus decision pathway provides practical guidance on when and in which patients nonstatin therapies may be considered. The document thereby provides recommendations on the use of newer nonstatin therapies until CVOTs with these therapies are completed and new cholesterol guidelines have been formulated.